Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,830 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.
Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Shimada T, Tsuya A, Fukuoka M, Minami H. Uryu K, et al. Among authors: imamura y. Cancer Chemother Pharmacol. 2024 Apr 8. doi: 10.1007/s00280-024-04666-4. Online ahead of print. Cancer Chemother Pharmacol. 2024. PMID: 38584202
Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Tsuya A, Fukuoka M, Minami H. Uryu K, et al. Among authors: imamura y. Jpn J Clin Oncol. 2024 Mar 9;54(3):319-328. doi: 10.1093/jjco/hyad162. Jpn J Clin Oncol. 2024. PMID: 37997468
The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer.
Nishimura M, Toyoda M, Takenaka K, Imamura Y, Chayahara N, Kiyota N, Mukohara T, Kotake T, Tsuji A, Saito K, Saito Y, Minami H. Nishimura M, et al. Among authors: imamura y. Cancer Chemother Pharmacol. 2016 Jun;77(6):1165-70. doi: 10.1007/s00280-016-3026-6. Epub 2016 Apr 21. Cancer Chemother Pharmacol. 2016. PMID: 27100735 Free PMC article.
Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.
Funakoshi Y, Fujiwara Y, Kiyota N, Mukohara T, Shimada T, Toyoda M, Imamura Y, Chayahara N, Tomioka H, Umezu M, Otsuki N, Nibu K, Minami H. Funakoshi Y, et al. Among authors: imamura y. Cancer Chemother Pharmacol. 2016 Feb;77(2):281-8. doi: 10.1007/s00280-016-2966-1. Epub 2016 Jan 20. Cancer Chemother Pharmacol. 2016. PMID: 26791871 Free PMC article.
Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).
Sai S, Toyoda M, Tobimatsu K, Satake H, Yasui H, Kimbara S, Koyama T, Fujishima Y, Imamura Y, Funakoshi Y, Kiyota N, Toyama H, Kodama Y, Minami H. Sai S, et al. Among authors: imamura y. Cancer Chemother Pharmacol. 2021 Jan;87(1):65-71. doi: 10.1007/s00280-020-04174-1. Epub 2020 Oct 24. Cancer Chemother Pharmacol. 2021. PMID: 33098471 Clinical Trial.
Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
Nagatani Y, Funakoshi Y, Suto H, Imamura Y, Toyoda M, Kiyota N, Yamashita K, Minami H. Nagatani Y, et al. Among authors: imamura y. J Cancer Res Ther. 2021 Jul-Sep;17(4):1093-1100. doi: 10.4103/jcrt.JCRT_1222_20. J Cancer Res Ther. 2021. PMID: 34528569 Free article.
1,830 results